Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients

2015 ◽  
Author(s):  
Todd Covey ◽  
Tjeerd Barf ◽  
Michael Gulrajani ◽  
Fanny Krantz ◽  
Bart van Lith ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Lymphocytic Leukemia ◽  
Target Coverage ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Btk Inhibitor

scholarly journals Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Blood ◽  
2014 ◽  
Vol 123 (8) ◽  
pp. 1207-1213 ◽  
Author(s):  
Jennifer A. Woyach ◽  
Engin Bojnik ◽  
Amy S. Ruppert ◽  
Matthew R. Stefanovski ◽  
Virginia M. Goettl ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Mouse Model ◽  
Tyrosine Kinase ◽  
Lymphocytic Leukemia ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Genetic Inactivation ◽  
Key Points

Key Points Kinase-functional BTK is important in the development and expansion of CLL. Both targeted genetic inactivation of BTK and inhibition of BTK by ibrutinib inhibit the development of CLL in the TCL1 mouse model.

Sign in / Sign up

Export Citation Format

Share Document